A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael A. Crone, Miles Priestman, Marta Ciechonska, Kirsten Jensen, David J. Sharp, Arthi Anand, Paul Randell, Marko Storch, Paul S. Freemont
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec35
record_format	dspace
spelling	oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec352021-12-02T17:19:41ZA role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics10.1038/s41467-020-18130-32041-1723https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec352020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18130-3https://doaj.org/toc/2041-1723The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.Michael A. CroneMiles PriestmanMarta CiechonskaKirsten JensenDavid J. SharpArthi AnandPaul RandellMarko StorchPaul S. FreemontNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
description	The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.
format	article
author	Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont
author_facet	Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont
author_sort	Michael A. Crone
title	A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_short	A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_full	A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_fullStr	A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_full_unstemmed	A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_sort	role for biofoundries in rapid development and validation of automated sars-cov-2 clinical diagnostics
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35
work_keys_str_mv	AT michaelacrone aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT milespriestman aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT martaciechonska aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT kirstenjensen aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT davidjsharp aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT arthianand aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulrandell aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT markostorch aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulsfreemont aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT michaelacrone roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT milespriestman roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT martaciechonska roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT kirstenjensen roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT davidjsharp roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT arthianand roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulrandell roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT markostorch roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulsfreemont roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
_version_	1718381017061916672

A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

Ejemplares similares